


RECEIVED

SEP 17 2001

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: application of: Linda C. Burkly

Group Art Unit: 1642

Serial No.: 09/234,290

Examiner: S. Ungar

Filed: January 20, 1999

For: *TREATMENT OF INSULIN DEPENDENT
DIABETES*

Attorney Docket No.: 10274-008003
(BGP-151CPCN)

Commissioner for Patents
Washington, D.C. 20231

1612
KD
Green

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

September 6, 2001
Date of Signature and of Mail Deposit

By:

Sandra Sturtevant
Sandra Sturtevant

AMENDMENT AND RESPONSE

Dear Sir:

This is in response to the non-final Office Action dated March 9, 2001 (Paper No. 14). A separate petition for the appropriate extension of time to respond is being filed concurrently herewith. Please amend the above-referenced application as follows:

In the specification:

Please replace the original Sequence Listing, pages 37-50, with the substitute Sequence Listing submitted herewith.

Replace the paragraph beginning at page 23, line 23, with the following rewritten paragraph:

The adoptive transfer experiment described in Example 1 was repeated with a VCAM-Ig fusion protein (VCAM 2D-IgG) instead of an anti-VLA-4 mAb. VCAM 2D-IgG is a soluble form of the ligand for VLA-4 (VCAM1) which consists of the two N-terminal domains of VCAM1 fused to the human IgG1 heavy chain constant region sequences (Hinges, CH2 and CH3). The VCAM 2D-IgG DNA sequence and its translated amino acid sequence are shown in

51